EyePoint Pharmaceuticals
EYPT
#5166
Rank
A$2.29 B
Marketcap
A$27.67
Share price
3.38%
Change (1 day)
100.09%
Change (1 year)

Revenue for EyePoint Pharmaceuticals (EYPT)

Revenue in 2025 (TTM): A$67.37 Million

According to EyePoint Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is A$63.87 Million. In 2024 the company made a revenue of A$69.57 Million an increase over the revenue in the year 2023 that were of A$67.54 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for EyePoint Pharmaceuticals from 2003 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$67.37 M-3.16%
2024 A$69.57 M3%
2023 A$67.54 M11.01%
2022 A$60.84 M19.41%
2021 A$50.95 M13.77%
2020 A$44.78 M53.98%
2019 A$29.08 M
2017 A$3.34 M-64.97%
2016 A$9.53 M301.92%
2015 A$2.37 M-93.09%
2014 A$34.35 M1296.52%
2013 A$2.45 M7.63%
2012 A$2.28 M-63.18%
2011 A$6.2 M-63.19%
2010 A$16.86 M14.73%
2009 A$14.69 M14.94%
2008 A$12.78 M1388.53%
2007 A$0.85 M-67.13%
2006 A$2.61 M41.16%
2005 A$1.85 M231.58%
2004 A$0.55 M133.7%
2003 A$0.23 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NRC Health
NRC
A$0.20 B 228.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Nymox Pharmaceutical
NYMX
N/AN/A Bahamas